Actualités Coeptis Therapeutics Holdings Inc - COEP | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer PR...

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage...

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic PR Newswire WEXFORD...

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering PR...

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering PR...

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market PR Newswire WEXFORD, Pa., June...

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer PR Newswire WEXFORD, Pa., May 17, 2023 15-year accounting and finance...

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature...

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical...

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform...

Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine

Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational...

Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling

Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling PR...

Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program

Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program PR...

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program PR Newswire WEXFORD, Pa., Nov. 22...

Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell

Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell PR Newswire WEXFORD, Pa., Nov. 15...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Coeptis Therapeutics Holdings Inc (COEP)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

COEP Actualités

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies

Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine

Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling

Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Coeptis Therapeutics Holdings Inc (COEP) Actualités

Coeptis Therapeutics Holdings Inc (COEP)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

COEP Actualités

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies

Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine

Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling

Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application